New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets
Open accessThe DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.
Abstract
To improve our ability to extrapolate preclinical toxicity to humans, there is a need to understand and quantify the concordance of adverse events (AEs) between animal models and clinical studies. In the present work, we discovered 3011 statistically significant associations between preclinical and clinical AEs caused by drugs reported in the PharmaPendium database of which 2952 were new associations between toxicities encoded by different Medical Dictionary for Regulatory Activities terms across species. To find plausible and testable candidate off-target drug activities for the derived associations, we investigated the genetic overlap between the genes linked to both a preclinical and a clinical AE and the protein targets found to interact with one or more drugs causing both AEs. We discuss three associations from the analysis in more detail for which novel candidate off-target drug activities could be identified, namely, the association of preclinical mutagenicity readouts with clinical teratospermia and ovarian failure, the association of preclinical reflexes abnormal with clinical poor-quality sleep, and the association of preclinical psychomotor hyperactivity with clinical drug withdrawal syndrome . Our analysis successfully identified a total of 77% of known safety targets currently tested in in vitro screening panels plus an additional 431 genes which were proposed for investigation as future safety targets for different clinical toxicities. This work provides new translational toxicity relationships beyond AE term-matching, the results of which can be used for risk profiling of future new chemical entities for clinical studies and for the development of future in vitro safety panels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Analytical inconsistencies also arise from the use of different statistical frameworks such as sensitivity, specificity, predictive values, or likelihood ratios, which can yield divergent conclusions (Monticello et al., 2017; Bailey and Balls, 2019; Giblin et al., 2021).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Giblin et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as repeatedly reported from previous concordance analyses (Clark and Steger-Hartmann, 2018; Giblin et al., 2021).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Giblin et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of the 188 adverse events that were identified as significant by Giblin et al. analysis, 183 (97%) were also significant in our dataset.”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Giblin et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scikit-learn: Machine Learning in Python
Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Müller, A., Nothman, J., Louppe, G., et al. (2012) · arXiv · doi:10.48550/arxiv.1201.0490 · Cited by 71,016
Lecture Notes in Computer Science 1205
(1999) · Industrial Robot: An International Journal · doi:10.1108/ir.1999.04926fae.001 · Cited by 38,662
On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P
Fisher, R. A. (1922) · Journal of the Royal Statistical Society · doi:10.2307/2340521 · Cited by 2,953
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A., Girón, C. G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1098 · Cited by 2,605
Entrez Gene: gene-centered information at NCBI
Maglott, D., Ostell, J., Pruitt, K. D., & Tatusova, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1237 · Cited by 2,094
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
UniProt Knowledgebase: a hub of integrated protein data
Magrane, M., & Consortium, U. (2011) · Database · doi:10.1093/database/bar009 · Cited by 1,463
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Research works printed but not linked: 16
- (16) Deaton, Aimee M.; Fan, Fan; Zhang, Wei; Nguyen, Phuong A.; Ward, Lucas D.; Nioi, Paul. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence. Toxicol. Sci. 2019 , 167 , 593-603. -
- (20) Nissen, David. Mosby's Drug Consult , 13th ed.; Mosby, 2007. -
- (21) Reed Elsevier Properties SA. PharmaPendium https://pharmapendium.com/ (accessed Jun 4, 2018). -
- (39) Süleyman, Halis; Demircan, Berna; Karagöz, Yalçin. Anti-Inflammatory and Side Effects of Cyclooxygenase Inhibitors. Pharmacol. Reports 2007 , 59 , 247-258. -
- (43) Ahmadian, Maryam; Suh, Jae Myoung; Hah, Nasun; Liddle, Christopher; Atkins, Annette R.; Downes, Michael; Evans, Ronald M. Pparγ Signaling and Metabolism: The Good, the Bad and the Future. Nat. Med. 2013 , 19 , 557-566. -
- (55) Whitebread, Steven; Hamon, Jacques; Bojanic, Dejan; Urban, Laszlo. Keynote Review: In Vitro Safety Pharmacology Profiling: An Essential Tool for Successful Drug Development. Drug Discov. Today 2005 , 10 , 1421-1433. - · DOI · Paper page
- (56) Santos, Cynthia; Olmedo, Ruben E. Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment. Emerg. Med. Pract. 2017 , 19 , 1-20. -
- (63) Haughey, Heather M.; Marshall, Erin; Schacht, Joseph P.; Louis, Ashleigh; Hutchison, Kent E. Marijuana Withdrawal and Craving: Influence of the Cannabinoid Receptor 1 ( CNR1 ) and Fatty Acid Amide Hydrolase ( FAAH ) Genes. Addiction 2008 , 103 , 16781686. -
- (72) Komori, Shinji; Kasumi, Hiroyuki; Sakata, Kazuko; Koyama, Koji. The Role of Androgens in Spermatogenesis. Soc. Reprod. Fertil. Suppl. 2007 , 63 , 25-30. -
- (78) Brown, Elliot G.; Wood, Louise; Wood, Sue. The Medical Dictionary for Regulatory Activities (MedDRA). In Drug Safety ; John Wiley & Sons, Ltd: Chichester, UK, 1999; Vol. 20, pp 109-117. -
- (81) Li, Wentian. Mutual Information Functions Versus Correlation Functions in Binary Sequences. J. Stat. Phys. 2012 , 60 , 249-252. -
- (89) Berthold, Michael R.; Cebron, Nicolas; Dill, Fabian; Gabriel, Thomas R.; Kötter, Tobias; Meinl, Thorsten; Ohl, Peter; Thiel, Kilian; Wiswedel, Bernd. KNIME - the Konstanz Information Miner. In ACM SIGKDD Explorations Newsletter ; Preisach C., Burkhardt H., Schmidt-Thieme L., Decker R., Ed.; Springer: Berlin, Heidelberg, 2009; Vol. 11, p 26. -
- (90) Krejsa, Cecile M.; Horvath, Dragos; Rogalski, Sherri L.; Penzotti, Julie E.; Mao, Boryeu; Barbosa, Frédérique; Migeon, Jacques C. Predicting ADME Properties and Side Effects: The BioPrint Approach. Curr. Opin. Drug Discov. Devel. 2003 , 6 , 470-480. -
- (107) Mungall, Christopher J.; Koehler, Sebastian; Robinson, Peter; Holmes, Ian; Haendel, Melissa. K-BOOM: A Bayesian Approach to Ontology Structure Inference, with Applications in Disease Ontology Construction. bioRxiv 2019 , 048843. -
- (108) Mohammed, Osama; Benlamri, Rachid; Fong, Simon. Building a Diseases Symptoms Ontology for Medical Diagnosis: An Integrative Approach. In 1st International Conference on Future Generation Communication Technologies, FGCT 2012 ; IEEE, 2012; pp 104-108. -
- (116) Mungall, Christopher J.; McMurry, Julie A.; Köhler, Sebastian; Balhoff, James P.; Borromeo, Charles; Brush, Matthew; Carbon, Seth; Conlin, Tom; Dunn, Nathan; Engelstad, Mark; Foster, Erin; Gourdine, J. P.; Jacobsen, Julius O. B.; Keith, Dan; Laraway, Bryan; Lewis, Suzanna E.; NguyenXuan, Jeremy; Shefchek, Kent; Vasilevsky, Nicole; et al. The Monarch Initiative: An Integrative Data and Analytic Platform Connecting Phenotypes to Genotypes across Species. Nucleic Acids Res. 2017 , 45 , D712-D722. -
Cited by
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 216
“163,164 Meanwhile, immunogenicity refers to the development of anti-drug antibodies (ADAs) by the patient ’ s immune system in response to the therapeutic mAb.”
Burnett, S. D., Blanchette, A. D., Chiu, W. A., & Rusyn, I. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00203 · Cited by 95
Nada, H., Sivaraman, A., Lu, Q., Min, K. H., Kim, S.-D., Goo, J., Choi, Y., & Lee, K. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01957 · Cited by 49
Introduction to Special Issue: Computational Toxicology
Kleinstreuer, N., Tetko, I. V., & Tong, W. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00032 · Cited by 30
Metadata
- Authors
- Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- University of Cambridge (GB)
- Safety Platforms, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom
- AstraZeneca (United States) (US)
- Corresponding author
- Giblin, Kathryn A.
- Bender, Andreas
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-18
- Volume
- 34
- Issue
- 2
- Pages
- 438-451
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W3117596366
- Cited by
- 18
- References
- 99
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- AstraZeneca (RG82499)
- FP7 Ideas: European Research Council (336159)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced adverse events, animal models, mutagenicity, teratozoospermia, ovarian failure, sleep quality, drug withdrawal syndrome
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Molecular Structure, Databases, Factual, Adverse Drug Reaction Reporting Systems, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.